- Home
- PCRX vs NVAX Comparison
PCRX vs NVAX Comparison
Compare PCRX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- NVAX
- Stock Information
- Founded
- PCRX 2006
- NVAX 1987
- Country
- PCRX United States
- NVAX United States
- Employees
- PCRX N/A
- NVAX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCRX Health Care
- NVAX Health Care
- Exchange
- PCRX Nasdaq
- NVAX Nasdaq
- Market Cap
- PCRX 1.2B
- NVAX 1.3B
- IPO Year
- PCRX 2011
- NVAX 1995
- Fundamental
- Price
- PCRX $25.12
- NVAX $5.98
- Analyst Decision
- PCRX Buy
- NVAX Buy
- Analyst Count
- PCRX 9
- NVAX 6
- Target Price
- PCRX $29.89
- NVAX $17.50
- AVG Volume (30 Days)
- PCRX 782.0K
- NVAX 8.5M
- Earning Date
- PCRX 05-08-2025
- NVAX 05-08-2025
- Dividend Yield
- PCRX N/A
- NVAX N/A
- EPS Growth
- PCRX N/A
- NVAX N/A
- EPS
- PCRX N/A
- NVAX 2.97
- Revenue
- PCRX $702,772,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- PCRX $9.48
- NVAX N/A
- Revenue Next Year
- PCRX $11.31
- NVAX N/A
- P/E Ratio
- PCRX N/A
- NVAX $2.01
- Revenue Growth
- PCRX 3.08
- NVAX 25.92
- 52 Week Low
- PCRX $11.16
- NVAX $4.43
- 52 Week High
- PCRX $31.67
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- PCRX 48.10
- NVAX 43.78
- Support Level
- PCRX $25.08
- NVAX $5.82
- Resistance Level
- PCRX $27.34
- NVAX $7.50
- Average True Range (ATR)
- PCRX 1.16
- NVAX 0.56
- MACD
- PCRX -0.18
- NVAX 0.00
- Stochastic Oscillator
- PCRX 48.85
- NVAX 8.71
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.